Back to top

 

Disclaimer

Eye
Mark Scott Brown, M. D
815.642.9504 (fax) mark@eyeplastics.com (email)

We subscribe to the HONcode principles of the Health On the Net Foundation
The HIPAA Policy is available at any MD's Office
Back to top

Back to top

Back to top
Orbital Tumors

Orbital Tumors - Lymphoma
    .

    General

    • almost exclusively in adults
    • continuum including benign reactive lymphoid hyperplasia (pseudolymphoma) to atypical lymphoid hyperplasia to low-grade then high grade malignant lymphoma;
    • also Orbital inflammatory syndrome pseudotumorplasmacytoma (including myeloma)
    • bimodal peak 30’s and 60’s
    • unilateral or bilateral
    • palpable rubbery mass fixed to orbital rim
    • maligant lymphoma & reactive lymphoid hyperplasia cause gradual (over a year or more) progressive, painless proptosis (vs. Obital inflammatory syndrome), lacrimal enlargement
    • usually on conjunctiva, anterior orbit so palpable or visible
    • eyelid or bilateral orbital involvement suggests systemic disease
    • putty-like molding to undisplaced tissues so little Visual Acuity (VA) or EOM loss; usually no bone erosion or infiltration unless high-grade lymphoma
    • lymphoma in retrobubar fat is infiltrative

    Imaging

    • all patients w/ orbital lymphoid lesions need exam for systemic lymphoma (by oncology) with orbital, abdominal, chest CT;
      • CBC
      • bone marrow biopsy
      • chest x-ray (CXR)
      • bone/liver/spleen scan

    Pathology

    • cytologic factors are more prognostic than mono/polyclonal; but
      • most benign lesions (reactive hyperplasia) are usually mostly T cells with polyclonal Bs;
      • malignant lymphoma usually more monoclonal B cells
    • both polyclonal and monoclonal varieties can develop systemic disease
    • open biopsy for path to give fresh tissue for touch preps; immunohistochemistry; flow cytometry; and gene rearrangement studies; in formalin for micro; gluteraldehyde for electron microscopy

    Treatment & Course

    • X-Ray Therapy (XRT) for most orbital lymphoid lesions that are confined to orbit (50% of lymphomas)
    • Chemotherapy for systemic, therapy can be controversial
    • Course
      • up to 25% of patients have systemic lymphoma later on with benign reactive hyperplasia:
      • 40% of patients get systemic involvlement within 5 years with atypical lymphoid hyperplasia:

       

     

 

   

 

 


Copyright © 1997-2005 EyePlastics.com If there is a problem with this web site please contact the Webmaster.